Abstract
Objectives From the perspective of Chinese healthcare system, this study compared the cost-utility of aripiprazole once-monthly (AOM) and paliperidone palmitate once-monthly injectable for the treatment of adult Chinese patients with schizophrenia.
Methods A 5-state Markov model was constructed to assess the cost-utility of 10 years of treatment with long-acting injections (LAI) for schizophrenia. The long-term costs and quality-adjusted life years (QALYs) were estimated. The outcome was the incremental cost-effectiveness ratio (ICER). The annual discount rate was set at 5 %. Willingness-to-pay (WTP) threshold of 1x GDP was used to judge the economics of intervention.
Results In the base-case, the incremental costs of AOM relative to PP1M after 10 years of treatment were US$1,926.373 with an incremental QALYs of 0.306. The ICER for AOM was US$6,285.303/QALY, which was lower than the WTP threshold of US$12,538.306/QALY. The one-way sensitivity analysis and probability sensitivity analysis verified the robustness of the base-case. Scenario analysis showed that from 10 to 30 years, as the horizon increased, the ICER became smaller, and all were below the WTP.
Conclusions This analysis showed that compared with PP1M, AOM represents a long-term cost-utility advantages for schizophrenia treatment in China.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
No
Clinical Protocols
No
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos